This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Homocystinuria / Classical homocystinuria / CBS deficiency호모시스틴뇨증 (유황함유아미노산대사장애)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E72.1 (homocystinuria, disorders of sulfur-containing amino acid metabolism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCBS deficiency (Cystathionine β-synthase deficiency), Hyperhomocysteinemia, Hypermethioninemia, Classical homocystinuria
C. Adult onsetLikelihood of first onset in adulthood not low — in mild pyridoxine (vitamin B6)-responsive patients, hyperhomocysteinemia is mild, so the disease may go undiagnosed in childhood and first present in adulthood with thromboembolism (cerebral infarction, pulmonary embolism), lens dislocation, or osteoporosis; non-B6-responsive cases may also be first diagnosed in adulthood in regions where they are not included in NBS.
1. History1962 Carson and Neill first detected homocystine in urine → 1964 Mudd and Finkelstein confirmed CBS enzyme deficiency → 1966 pyridoxine-responsive type discovered → 1985 CBS gene cloned → 1990s betaine treatment established → 2024 pegtivatinase phase 3 completed.
2. CausesCBS gene (21q22.3, encoding cystathionine β-synthase) mutations → CBS enzyme deficiency → blocked conversion of methionine → cystathionine → accumulation of homocysteine and methionine in blood and urine, decreased cysteine. Pyridoxine-responsive type (about 50%): residual CBS activity present.
3. GeneticsAutosomal recessive. CBS gene (21q22.3), 23 exons. Most common variants: I278T (pyridoxine-responsive), G307S (nonresponsive). More than 160 variants worldwide. Homozygous/compound heterozygous. I278T homozygotes: relatively mild phenotype.
4. General epidemiologyAbout 1 in 200,000~335,000 births worldwide. Early diagnosis possible in regions where it is included in national newborn screening. 1 in 65,000 births in Ireland (founder mutation effect). Korea: some cases found through measurement of methionine concentration in NBS.
5. PathophysiologyCBS enzyme deficiency → homocysteine accumulation → ① vascular endothelial injury (toxicity to vascular endothelial cells, promotion of thrombosis) → arterial and venous thromboembolism. ② Disruption of fibrillin sulfur bonds → weakening of lens suspensory ligaments → lens dislocation. ③ Impaired bone collagen cross-linking → osteoporosis and skeletal abnormalities (Marfan-like). ④ Direct central nervous system toxicity → intellectual disability and seizures.
6. SymptomsInvolvement of four major systems: ① eye (lens dislocation, myopia, glaucoma), ② skeleton (Marfan-like habitus, scoliosis, pectus excavatum, osteoporosis), ③ blood vessels (arterial and venous thromboembolism, cerebral infarction, pulmonary embolism), ④ central nervous system (intellectual disability, seizures, behavioral abnormalities). More severe and earlier onset in the non-B6-responsive type.
7. SignsLens dislocation (downward; upward in Marfan), severe myopia. Arachnodactyly, increased height, reduced upper-to-lower segment ratio. Scoliosis and kyphosis. Reduced bone density (DXA). Serum total homocysteine >100 μmol/L (severe), elevated serum methionine, decreased cysteine. Positive urine homocystine (oxidation detection).
8. ScreeningNewborn screening (NBS): quantification of serum methionine (tandem MS-based). If methionine is elevated, serum total homocysteine is additionally measured. Methionine measurement is included in Korean NBS. High-risk families (siblings): CBS gene analysis. Adults with recurrent thromboembolism: screening by serum total homocysteine measurement.
9. DiagnosisSerum total homocysteine >100 μmol/L + elevated serum methionine + decreased plasma cysteine. Positive urine homocystine (nitroprusside reaction, HPLC). CBS enzyme activity (liver biopsy or skin fibroblasts). CBS gene NGS analysis. Pyridoxine responsiveness test (100 mg B6/day × 4~6 weeks; responsive type if homocysteine decreases by >50%).
10. TreatmentPyridoxine-responsive type: vitamin B6 (pyridoxine) 150~500 mg/day → goal of normalizing homocysteine. Betaine 3~6 g/day (in 2 divided doses): promotes conversion of homocysteine → methionine through the CBS bypass pathway (remethylation). Low-methionine diet with cysteine supplementation (central in the non-B6-responsive type). Folic acid, B12, and B6 supplementation. Thrombosis prevention: aspirin, anticoagulants (if history of thrombosis). Pegtivatinase (enzyme replacement), phase 3 completed in 2024: CBS bypass enzyme therapy.
11. PrognosisWith NBS + early treatment, intellectual disability and thromboembolism are mostly preventable. If untreated, thromboembolism occurs in about 50% by age 30, lens dislocation in about 82%, and intellectual disability in about 64%. In the pyridoxine-responsive type, normalization is possible with B6 alone. Prognosis is also greatly improved with betaine and dietary treatment. Long-term treatment adherence is the decisive prognostic factor.
12. PreventionPrimary: genetic counseling (recurrence risk 25%), early diagnosis through inclusion in NBS. Secondary: immediate further testing when methionine is elevated on NBS → early start of dietary and pyridoxine treatment after confirmation. Tertiary: regular monitoring of serum homocysteine (target <15 μmol/L), thrombosis prevention, regular eye examinations (lens dislocation), bone density testing.
13. ReferencesMudd SH et al. Am J Hum Genet. 1985 … and 9 other papers

1. History

The history of homocystinuria began in 1962 when Norman Carson and James B. Neill of Belfast, UK, discovered homocystine in the urine of children with intellectual disability and seizures. This discovery benefited from the then-new analytical technique of urine amino acid chromatography. In 1964, S. Harvey Mudd and Jerome D. Finkelstein confirmed that cystathionine β-synthase (CBS) activity was deficient in the liver tissue of these patients, establishing the cause at the molecular level.

In 1966, Gaull and colleagues discovered that pyridoxine (vitamin B6) markedly lowered homocysteine concentrations in some patients via PLP (pyridoxal 5'-phosphate), the coenzyme of CBS, showing that there are two clinical phenotypes: pyridoxine-responsive and pyridoxine-nonresponsive. In 1968, Brenton and colleagues reported that a low-methionine diet reduced homocysteine accumulation.

In 1985, Kraus and colleagues cloned the CBS gene on the long arm of chromosome 21 (21q22.3), and subsequently I278T (associated with the pyridoxine-responsive type) and G307S (associated with the nonresponsive type) were identified as the most common pathogenic variants. In the 1990s, betaine was introduced into treatment based on its pharmacological mechanism of converting homocysteine to methionine via the remethylation pathway. Since the 2000s, MS/MS-based methionine measurement in newborn screening (NBS) has been standardized, enabling early diagnosis and treatment. In 2024, the enzyme therapeutic pegtivatinase (PEGylated cystathionine lyase) completed a phase 3 clinical trial (COMPOSE) in CBS deficiency and is drawing attention as a new treatment option.

In Korea, homocystinuria is included in newborn screening (blood methionine measurement), and some patients are detected early. Korean case reports and genetic analysis data are accumulating, and special formula and low-methionine dietary management are supported through the health insurance coverage system.


2. Causes

Homocystinuria (CBS deficiency) is an autosomal recessive genetic disorder caused by deficient cystathionine β-synthase (CBS) enzyme activity due to pathogenic variants of the CBS gene, located on the long arm of chromosome 21 (21q22.3).

In the sulfur-containing amino acid metabolic pathway, the CBS enzyme catalyzes the reaction that condenses homocysteine and serine to produce cystathionine. When CBS is deficient, this reaction is blocked, and homocysteine accumulates at the upstream step. Blood total homocysteine (tHcy) concentrations rise from 5~15 μmol/L in healthy individuals to 100~500 μmol/L or more in untreated CBS-deficient patients. At the same time, methionine accumulates (400~2,000 μmol/L), and the next metabolites, cystathionine and cysteine, decrease.

More than 160 pathogenic variants of the CBS gene have been reported worldwide. The most common variant is I278T (isoleucine-threonine substitution, 21q22.3), mainly associated with the pyridoxine-responsive type, and G307S (glycine-serine substitution) is associated with the nonresponsive type. The CBS enzyme uses pyridoxal 5'-phosphate (PLP, the active form of vitamin B6) as a coenzyme. The I278T variant enzyme has reduced PLP affinity, so its activity is reduced at physiological PLP concentrations, but when PLP concentrations rise with high-dose pyridoxine supplementation, enzyme activity is restored to some extent.


3. Genetics

Homocystinuria (CBS deficiency) follows an autosomal recessive mode of inheritance. The CBS gene is located on the long arm of chromosome 21 (21q22.3), is about 28 kb in size, and consists of 23 exons. Affected patients are homozygous or compound heterozygous, with pathogenic variants on both alleles of the CBS gene.

There are clinically important genotype-phenotype associations. I278T homozygous patients are pyridoxine-responsive and show a relatively mild phenotype, and blood homocysteine can often be normalized with pyridoxine treatment alone. G307S homozygous or G307S compound heterozygous patients are pyridoxine-nonresponsive and are associated with a more severe phenotype. In compound heterozygous patients (I278T/G307S, etc.), the phenotype is determined by the residual enzyme activity of each of the two variants.

Prediction of pyridoxine responsiveness from genotype alone is incomplete, and a clinical pyridoxine responsiveness test (a decrease in tHcy of 50% or more after high-dose pyridoxine) is the standard. Heterozygous carriers are clinically asymptomatic, but in some, serum tHcy is mildly elevated, and this has been proposed as a risk factor for premature coronary artery disease (incompletely confirmed). The recurrence risk for siblings is 25%.


4. General epidemiology

Homocystinuria (CBS deficiency) occurs worldwide at a frequency of about 1 in 200,000~335,000 births. This frequency was estimated in symptom-based diagnostic cohorts before newborn screening was introduced, and diagnosis through NBS tends to show a somewhat lower frequency. In Ireland, a relatively high frequency of about 1 in 65,000 births is reported because of a founder mutation (I278T) effect.

The sex distribution is equal between males and females, and the racial and ethnic distribution is also fairly even worldwide. The pyridoxine-responsive type accounts for about 50% of all cases, and the nonresponsive type for the remaining about 50%. The phenotype of the responsive type is relatively mild, so some cases are not diagnosed in childhood and are first discovered in adulthood through thromboembolism or lens dislocation.

In Korea, some patients are detected early through newborn screening (blood methionine measurement, MS/MS-based). In a study analyzing Korean newborn screening results, the incidence of homocystinuria was reported at about 1 in 300,000~400,000 births. The number of patients registered and managed for CBS deficiency in Korea is estimated to be in the tens, but accurate statistics are limited.


5. Pathophysiology

The multisystem lesions of homocystinuria (CBS deficiency) are the direct result of excess homocysteine accumulation and cysteine deficiency.

Mechanism of vascular toxicity: homocysteine is directly toxic to vascular endothelial cells, causing endothelial dysfunction, oxidative stress, and endothelial cell apoptosis. At the same time, it promotes thrombus formation through platelet activation and activation of coagulation factors (V, XII, inhibition of tissue plasminogen activator). Through this mechanism, arterial (coronary, cerebral, peripheral arteries) and venous (deep vein thrombosis, pulmonary embolism) thromboses occur. In untreated patients, the incidence of thromboembolism by age 30 reaches about 50%.

Mechanism of connective tissue toxicity: homocysteine interferes with disulfide bond formation in fibrillin (fibrillin-1), reducing connective tissue strength. The suspensory ligament of the lens (zonule of Zinn) is rich in fibrillin, and damage to these bonds causes lens dislocation (ectopia lentis). In CBS deficiency, the lens tends to dislocate downward, distinguishing it from Marfan syndrome, which shows upward dislocation. Cross-linking of bone collagen is also impaired, resulting in osteoporosis and a Marfan-like habitus (arachnodactyly, increased height).

Mechanism of central nervous system toxicity: homocysteine overactivates N-methyl-D-aspartate (NMDA) receptors, causing glutamate toxicity (excitotoxicity), impairs mitochondrial function, and alters DNA methylation patterns, affecting neurodevelopment and cognitive function. This results in intellectual disability, seizures, and psychiatric symptoms.


6. Symptoms

The clinical symptoms of homocystinuria (CBS deficiency) involve four major organ systems (eye, skeleton, blood vessels, nervous system), presenting relatively mildly in the pyridoxine-responsive type and more severely in the nonresponsive type.

Ocular symptoms: lens dislocation (ectopia lentis) occurs in about 82% of diagnosed patients, beginning within the first few years of life and progressing. The lens is displaced downward and nasally, causing monocular diplopia, severe myopia, and reduced vision. Secondary glaucoma may develop, causing visual field defects and optic nerve damage. Lens dislocation can trigger an acute glaucoma crisis.

Skeletal symptoms: a body habitus similar to Marfan syndrome (marfanoid habitus) is characteristic. Increased height, reduced upper-to-lower segment ratio (increased lower segment), long slender fingers (arachnodactyly), chest wall deformities (pectus excavatum or pectus carinatum), and scoliosis and kyphosis appear. Vertebral compression fractures and other pathological fractures due to osteoporosis occur in adolescence~adulthood.

Vascular symptoms: thromboembolism is the most serious, life-threatening complication. Deep vein thrombosis, pulmonary embolism, cerebral infarction, myocardial infarction, and peripheral arterial occlusion occur. About 50% of untreated patients experience a thrombotic event before age 30. The risk of thrombosis increases markedly with surgery, prolonged immobilization, and dehydration.

Neurological symptoms: intellectual disability (mild~moderate) appears in about 64% of untreated non-B6-responsive patients. Seizures, behavioral disorders, psychosis, and depression are also present. In the pyridoxine-responsive type, neurological complications can mostly be prevented with NBS + early treatment.


7. Signs

The physical signs of homocystinuria (CBS deficiency) reflect the involvement of four systems and provide key clues for diagnosis.

Ophthalmic signs: slit-lamp examination confirms lens dislocation (downward, nasal displacement). Fundus examination may show myopic changes, macular abnormalities, and optic nerve abnormalities. Severe myopia on refraction. Elevated intraocular pressure (secondary glaucoma).

Skeletal signs: marfanoid habitus: increased height-to-weight ratio, long slender fingers with the thumb protruding beyond the palm (Steinberg thumb sign), positive wrist test (Walker-Murdoch wrist sign). Chest wall deformity (pectus excavatum, pectus carinatum). Scoliosis and kyphosis. Joint hyperlaxity is less than in Marfan syndrome.

Blood test signs: serum total homocysteine (tHcy) >100 μmol/L (100~500 μmol/L in severe cases). Elevated plasma methionine (400~2,000 μmol/L vs. normal 10~40 μmol/L). Decreased plasma cystathionine and cysteine. Positive urine homocystine (nitroprusside reaction or HPLC). Tendency to platelet hyperaggregation.

Imaging findings: reduced bone density on DXA (spine, hip). Evidence of compression fractures on spine X-rays. Evidence of cerebral infarction on brain MRI (after thrombotic events).


8. Screening

Screening for homocystinuria (CBS deficiency) consists of newborn screening (NBS) and clinical screening of high-risk groups.

Newborn screening: in NBS, serum methionine concentration is measured by tandem mass spectrometry (MS/MS). If methionine is elevated (cutoff >50~80 μmol/L), homocystinuria is suspected and confirmatory quantification of plasma total homocysteine (tHcy) is performed. Korean newborn screening includes methionine in amino acid profile analysis, enabling early detection of homocystinuria. However, false-negative cases of the pyridoxine-responsive type passing the NBS cutoff have been reported, so confirmatory testing is needed when there is clinical suspicion, regardless of NBS results.

Screening based on clinical suspicion: serum tHcy measurement is performed as screening in the following clinical situations: ① lens dislocation in children and adolescents, ② marfanoid habitus + lens or vascular abnormalities, ③ unexplained thromboembolism (DVT, cerebral infarction, pulmonary embolism) in adolescence~adulthood, ④ early-onset osteoporosis. ⑤ Siblings with a family history of CBS deficiency.

Pyridoxine responsiveness test: after confirmation, pyridoxine 100 mg/day is given for 4~6 weeks and tHcy is then measured. If tHcy decreases by 50% or more, the patient is classified as pyridoxine-responsive, and the treatment approach changes.


9. Diagnosis

Homocystinuria (CBS deficiency) is confirmed by quantification of plasma total homocysteine, enzyme activity measurement, and genetic analysis.

Quantification of plasma total homocysteine (tHcy): plasma tHcy is quantified by HPLC or LC-MS/MS. In CBS-deficient patients, tHcy >100 μmol/L (100~500 μmol/L in some severe cases). Elevated plasma methionine (400~2,000 μmol/L). Decreased plasma cystathionine and cysteine. Positive urine homocystine (disulfide): nitroprusside reaction or HPLC.

CBS enzyme activity measurement: CBS enzyme activity is measured in liver biopsy tissue or cultured skin fibroblasts. In CBS-deficient patients, residual activity is <1~2% of normal. In the pyridoxine-responsive type, residual activity may be 5~10% or more. Because this test is invasive, genetic analysis is mainly used.

CBS gene analysis: pathogenic variants are identified by NGS-based single-gene testing (CBS). Identification of I278T, G307S, and other variants. The variant type is used as a reference for predicting pyridoxine responsiveness, but a clinical responsiveness test is essential.

Differential diagnosis: Marfan syndrome (FBN1 variants, upward lens dislocation, normal homocysteine), hyperhomocysteinemia from other causes (folate or B12 deficiency, MTHFR variant-related), lens dislocation from other causes (trauma, Weill-Marchesani syndrome).


10. Treatment

The goal of treatment of homocystinuria (CBS deficiency) is to lower blood homocysteine concentrations as much as possible to prevent vascular, ocular, skeletal, and neurological complications.

Pyridoxine (vitamin B6) treatment: in pyridoxine-responsive patients (about 50% of all patients), if blood tHcy decreases by 50% or more with oral pyridoxine 150~500 mg/day, this dose is maintained as far as possible. In complete responders, tHcy can be maintained within the normal range (<15 μmol/L). The neuropathic side effects of pyridoxine are rare at 500 mg/day or less. Folic acid (5 mg/day) and vitamin B12 are supplemented together.

Betaine treatment: betaine (trimethylglycine, Cystadane) 3~6 g/day in 2 divided doses. It activates the complementary pathway that remethylates homocysteine to methionine via betaine-homocysteine methyltransferase (BHMT). Used in both pyridoxine-nonresponsive and responsive types. Methionine may rise further during betaine treatment, and caution is needed because hypermethioninemia carries a risk of cerebral edema.

Low-methionine diet with cysteine supplementation: natural protein restriction (low methionine) + amino acid mixture formula (supplementing cysteine and other essential amino acids). Dietary treatment is central in the pyridoxine-nonresponsive type. When started from the neonatal period, the effect in preventing intellectual disability is dramatic.

Thrombosis prevention: antiplatelet agents (aspirin) or anticoagulants in patients with a history of thrombosis. Advance preparation for the increased thrombotic risk during surgery (hydration, prophylactic heparin). Caution during long-distance travel and immobilization.

Other management: lens dislocation: correction with glasses, lens removal surgery if progressive. Osteoporosis: calcium and vitamin D supplementation, bisphosphonates (in adults). Seizures: anticonvulsants. Pegtivatinase (PEGylated cystathionine lyase), which completed phase 3 in 2024, is an enzyme replacement strategy that bypasses CBS and is expected to become a major treatment option in the future.


11. Prognosis

The prognosis of homocystinuria (CBS deficiency) varies greatly depending on the timing of diagnosis, treatment approach, and phenotype (pyridoxine-responsive/nonresponsive).

Prognosis with NBS + early treatment: if diagnosed in the neonatal period by NBS and treatment (diet ± pyridoxine ± betaine) is started immediately, most cases of intellectual disability, lens dislocation, and thromboembolism can be prevented. In long-term follow-up cohorts, intellectual development in patients who received early treatment after NBS is close to normal, and thrombotic events are markedly fewer.

Prognosis when untreated or treated late: in untreated patients, by age 30 thromboembolism occurs in about 50%, lens dislocation in about 82%, intellectual disability in about 64%, and complications such as vertebral compression fractures occur. There is a risk of early death from cerebral infarction or pulmonary embolism.

Prognosis of the pyridoxine-responsive type: complete responders whose tHcy normalizes with pyridoxine alone have a very good prognosis. Partial responders require combined pyridoxine + betaine + dietary treatment, and their prognosis is proportional to the level of tHcy control.

Long-term management: with dietary treatment (low-methionine special formula), reduced adherence due to taste, smell, and social inconvenience is a major problem. Self-management ability and education in adulthood are decisive for long-term prognosis. Serum tHcy is measured regularly (target <15 μmol/L) to monitor treatment response.


12. Prevention

Prevention of homocystinuria (CBS deficiency) consists of early diagnosis through newborn screening and treatment to prevent complications.

Primary prevention: genetic counseling for families of CBS-deficient patients explains the recurrence risk (25%) and recommends sibling screening (tHcy or CBS gene). Preimplantation genetic testing (PGT-M) or prenatal diagnosis is offered. Including methionine measurement in newborn screening enables treatment before diagnosis.

Secondary prevention: when methionine is elevated on NBS, immediate confirmation of plasma tHcy → after confirmation, dietary and pyridoxine treatment started within the first few weeks of life. Responsiveness is determined early by the pyridoxine responsiveness test to decide the treatment approach. Thrombosis prevention: thrombotic risk assessment and prophylactic anticoagulation before surgery and invasive procedures. Regular eye examinations (every 6~12 months): early detection and correction of lens dislocation. Regular bone density measurement (every 2~3 years from adulthood): early detection and treatment of osteoporosis.

Tertiary prevention: serum tHcy is measured every 3~6 months to check whether the treatment target (<15 μmol/L) is achieved. Multidisciplinary management by dietitians, pediatric neurology, and an inherited metabolic disease specialist team is provided to support adherence to dietary treatment. Patients and families are educated on warning signs of thrombosis (sudden one-sided paralysis, chest pain, leg swelling and pain) and on emergency response.


13. References

  1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1–31. PMID: 3871475.

  2. Picker JD, Levy HL. Homocystinuria caused by cystathionine beta-synthase deficiency. In: GeneReviews [Internet]. 2014 (updated 2019). PMID: 20301697.

  3. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metab. 2010;99(1):1–3. DOI: 10.1016/j.ymgme.2009.09.009 PMID: 19804993.

  4. Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21(7):738–747. DOI: 10.1023/a:1005445132327 PMID: 9839822.

  5. Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, et al. Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. J Pediatr. 2010;156(3):427–432. DOI: 10.1016/j.jpeds.2009.09.054 PMID: 19914637.

  6. Morris AA, Kozich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40(1):49–74. DOI: 10.1007/s10545-016-9979-0 PMID: 27778219.

  7. Kraus JP, Janosik M, Kozich V, et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 1999;13(5):362–375. DOI: 10.1002/(SICI)1098-1004(1999)13:5<362::AID-HUMU4>3.0.CO;2-K PMID: 10220141.

  8. Kluijtmans LA, Boers GH, Kraus JP, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999;65(1):59–67. DOI: 10.1086/302439 PMID: 10364517.

  9. Schiff M, Benoist JF, Tilea B, et al. Isolated remethylation disorders: do our treatments benefit patients? J Inherit Metab Dis. 2011;34(1):137–145. DOI: 10.1007/s10545-010-9120-x PMID: 20532994.

  10. Bublil EM, Majtan T, Park I, et al. Enzyme replacement with PEGylated cystathionine beta-synthase ameliorates homocystinuria in murine model. J Clin Invest. 2016;126(7):2372–2378. DOI: 10.1172/JCI85396 PMID: 27214551.